| Literature DB >> 18239127 |
Masataka Asagiri1, Toshitake Hirai, Toshihiro Kunigami, Shunya Kamano, Hans-Jürgen Gober, Kazuo Okamoto, Keizo Nishikawa, Eicke Latz, Douglas T Golenbock, Kazuhiro Aoki, Keiichi Ohya, Yuuki Imai, Yasuyuki Morishita, Kohei Miyazono, Shigeaki Kato, Paul Saftig, Hiroshi Takayanagi.
Abstract
Cathepsin K was originally identified as an osteoclast-specific lysosomal protease, the inhibitor of which has been considered might have therapeutic potential. We show that inhibition of cathepsin K could potently suppress autoimmune inflammation of the joints as well as osteoclastic bone resorption in autoimmune arthritis. Furthermore, cathepsin K-/- mice were resistant to experimental autoimmune encephalomyelitis. Pharmacological inhibition or targeted disruption of cathepsin K resulted in defective Toll-like receptor 9 signaling in dendritic cells in response to unmethylated CpG DNA, which in turn led to attenuated induction of T helper 17 cells, without affecting the antigen-presenting ability of dendritic cells. These results suggest that cathepsin K plays an important role in the immune system and may serve as a valid therapeutic target in autoimmune diseases.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18239127 DOI: 10.1126/science.1150110
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728